Genelux (GNLX) Cash from Financing Activities (2022 - 2026)
Genelux (GNLX) posted quarterly Cash from Financing Activities of $18.5 million for Q1 2026, up 93.77% year-over-year from $9.6 million in Q1 2025, and up 6616.67% quarter-over-quarter from $276000.0 in Q4 2025.
Genelux (GNLX) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Genelux's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $18.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 93.77% year-over-year to $18.5 million; the TTM figure through Mar 2026 stood at $18.9 million (down 49.54% YoY), while the FY2025 annual figure was $9.9 million, down 65.29% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $18.5 million, up from $276000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $27.7 million in Q2 2024, with the low at -$130000.0 in Q1 2022.
- The 5-year median for Cash from Financing Activities is $688000.0 (2024), against an average of $7.8 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 11361.54% in 2023, then tumbled 99.81% in 2025.
- Genelux's Cash from Financing Activities stood at $545000.0 in 2022, then fell by 26.42% to $401000.0 in 2023, then plunged by 77.31% to $91000.0 in 2024, then jumped by 203.3% to $276000.0 in 2025, then surged by 6616.67% to $18.5 million in 2026.
- Business Quant data shows GNLX's Cash from Financing Activities at $18.5 million in Q1 2026, $276000.0 in Q4 2025, and $52000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 18.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.54 Mn |
| Mar 31, 2026 | 18.54 Mn |
| Dec 31, 2025 | 276,000.00 |
| Dec 31, 2025 | 276,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | 9.57 Mn |
| Mar 31, 2025 | 9.57 Mn |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Jun 30, 2024 | 27.73 Mn |
| Jun 30, 2024 | 27.73 Mn |
| Mar 31, 2024 | 688,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Dec 31, 2023 | 401,000.00 |
| Sep 30, 2023 | 6.36 Mn |
| Sep 30, 2023 | 6.36 Mn |
| Jun 30, 2023 | 22.62 Mn |
| Jun 30, 2023 | 22.62 Mn |